The European Commission has put forward the European Radioisotope Valley Initiative (C/2026/6132) a new strategic framework to strengthen Europe’s leadership in the production of medical radioisotopes. It aims to reinforce EU security of radioisotope supply, guiding investment in the sector and reducing strategic dependencies on third countries, in particular Russia.  

With more than 10 million medical procedures using radioisotopes performed in the EU every year, mainly in oncology and cardiology, an impressive EU-wide production and distribution network has been developed to supply radioisotopes to patients across Europe daily. The EU has become the world’s leading producer of medical radioisotopes, exporting about half of its production overseas. However, critical parts of the European supply chain are exposed to dependencies on foreign suppliers, ageing production facilities, and competition from alternative suppliers, thereby creating the risk of investment displacement and higher costs. Furthermore, the global demand for medical radioisotopes, as well as the pace of innovation in this area, are increasing. Today’s ERVI communication responds to these challenges by defining a coordinated approach to supporting investments in research and development, bringing innovation to market, addressing value chain dependencies, and increasing production capacity. It also provides a direct contribution to the REPowerEU Roadmap towards ending Russian energy imports.

The Communication establishes five strategic priorities and 10 actions.

Research & Development and bringing innovations to market

The Commission will support research and innovation into the next-generation medical radioisotopes, radiopharmaceuticals and production technologies. A Strategic Research and Innovation Agenda (SRIA) - as used in other sectors - will help better connect research with market needs and patients. Instruments such as the emerging IPCEI for innovative nuclear technologies, the European Innovation Council, and new European partnerships can help mobilize public and private investment to accelerate innovation deployment. 

Investments in production facilities to ensure security of supply

The initiative aims to guide and support Member States and industry investments across the medical radioisotope value chain to strengthen the resilience and localisation of EU supply. Priorities include the development of EU-based metallic High Assay Low Enriched Uranium (HALEU) capacity and production of stable isotopes currently imported from Russia, as well as upgrades of existing reactors and construction of new production facilities. Member states should make use of the EU Startup and Scaleup Strategy, the SGEI State aid framework and the recent Critical Medicines Act for which the political agreement was achieved this year to support these efforts, while the Commission will explore ways to better combine public and private financing.

Market Monitoring and Forecasting

The Commission will act to improve the visibility of supply and demand trends and assess the investment needs of the European market for radioisotopes. This work will build upon the European Observatory on the Supply of Medical Radioisotopes and rely on continuing involvement of Member States and stakeholders, while making full use of the new EU mechanisms for tackling shortages of essential medicines.

Developing strategic international partnerships

ERVI will support cooperation with trusted international partners to diversify supply chains, strengthen resilience and promote scientific and industrial collaboration. In particular, the continuing cooperation with our partners in the UK and US is crucial for developing a resilient supply chain for metallic High Assay Low Enriched Uranium (HALEU).

Supporting an evolving regulatory framework

The Commission will cooperate with the International Atomic Energy Agency to support reliable international transport of medical radioisotopes and explore further measures to facilitate transport between Member States. A further step will be to pursue the streamlining of EU and national procedures for radiation protection and waste management in nuclear medicine to support patients’ access to innovative treatments.

Background

In June 2024, the Council called on the Commission to seek to maintain Europe’s global leadership role in the supply of medical radioisotopes and make tangible and swift progress on developing ambitious ‘building blocks’ for specific actions. 

In order to define the objectives and architecture of ERVI, the Commission carried out extensive consultations involving stakeholders and member states and published a feasibility study in March 2026.

The initiative also builds on the Strategic Agenda for Medical Ionising Radiation Applications (SAMIRA), adopted by the Commission in 2021 to strengthen the secure supply of medical radioisotopes, improve quality and safety in radiation medicine, and support innovation in nuclear medicine technologies.

In May 2025, the REPowerEU road map further highlighted the need to increase EU production capacities, reduce dependency on Russia and strengthen the resilience of the European medical radioisotope supply chain. The establishment of ERVI was identified as one of the roadmap’s key actions.

Related links

• Communication on the European Radioisotope Valley Initiative (C/2026/6132)
• European Radioisotope Valley Initiative
• ERVI feasibility study
• SAMIRA – Strategic Agenda for Medical Ionising Radiation Applications
• European Observatory on the Supply of Medical Radioisotopes

Two skeletons from the Indonesian island of Sulawesi had something strange going on in their mouths. Not cavities. Not the usual wear from a tough diet. Deep, rounded grooves cut into the teeth — a pattern no archaeologist had documented before, and one nobody could explain. The answer, published in Science Advances, pushes the known […]

Mounjaro was first approved by the FDA in 2022 for improving blood sugar control in adults with type 2 diabetes.

The post FDA approves Mounjaro to protect high-risk diabetes patients from heart risks appeared first on BOL News.

Carleton Gajdusek won the Nobel Prize for his work on a disease in Papua New Guinea. But his biggest experiment was on the children he took from the field to the US—many of whom he sexually molested, with the knowledge and, in some cases, approval of his professional peers and colleagues:

In his journals and in letters to colleagues, Gajdusek was self-righteous, arguing that what he’d done was “no more serious than lying on the grass or picking a dandelion,” and he cited the Anga initiation rites as justification. These ceremonies had brought boys into their communities, as part of a shared passage into manhood, but Gajdusek treated them as a timeless license for the acts that he’d committed privately, one boy at a time. George Klein, a professor at the Karolinska Institute, in Stockholm, who was part of the Nobel Assembly for thirty-six years, validated Gajdusek’s opinions, telling him that he wondered if “the Western world can ‘catch up with you.’” He wrote, “I share your indignation about the typically Jewish-Christian-Moslem hypocrisy on sexual matters.” Gajdusek was troubled, though, by how many colleagues wrote letters saying that they knew the charges must be untrue. “I thought better of my friends,” he said. “They are dissimulating and lying.”

In this harrowing, incredibly reported story co-published by Science and Retraction Watch, Brendan Borrell uncovers how “Mei,” a 6-year-old girl in China, died a week after an experimental gene-editing trial went wrong—and how her medical team, led by neuroscientist Zilong Qiu, downplayed the risks to her parents, did not publicly disclose her death, and has faced no real accountability.

On 23 March 2025, the day before the procedure, the family settled into a shared room inside a crowded pediatric ward. When the other girl in the room broke into tears, Mei handed her one of her favorite stuffed animals: a blue bird. “She liked to give things to other kids,” Jason said.

The next day Mei put on a brave face as she was taken to the procedure room. Yu’s handpicked doctor inserted a needle between two vertebrae on her lower back and withdrew just over a teaspoon of spinal fluid to create space for the drug. Then, he swapped syringes and gently pressed down on the plunger, filling her spinal canal with viruses.

For Men’s Health, Brian Underwood investigates the flood of sunscreen misinformation on Instagram and TikTok, where influencers push inaccurate data about chemical UV filters, play chemist and promote their own DIY formulas, or even encourage no sun protection at all. Underwood sorts fact from fear, talking with dermatologists, chemists, and professionals who are working to reshape the messaging around sun exposure and sunscreen.

Environmental concerns may have also shown up in your feed, with suggestions that these same filters are poisoning our oceans, giving rise to a whole category of sunscreens labeled “reef safe”—a meaningless marketing term that’s not regulated by the FDA (the same goes for products labeled “natural” or “organic”). Dr. Nelson’s point about “low-relevance models” is something to consider here too: The research demonstrating that oxybenzone, octinoxate, and other active ingredients may lead to reef bleaching was done in a lab setting where coral was exposed to levels of these chemicals significantly higher than has been found in the natural environment. It conveniently left out the fact that inorganic filters like zinc oxide (the one typically used in “reef safe” formulas) would have the same effect in similar doses.